Cell Death-based Treatment of Lung Adenocarcinoma

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2018 Jan 27

PMID 29371589

Citations 375

Authors

Tatiana V Denisenko

Inna N Budkevich

Boris Zhivotovsky

Affiliations

Soon will be listed here.

Abstract

The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of all lung cancer cases. In spite of achievements in understanding the pathogenesis of this disease and the development of new approaches in its treatment, unfortunately, lung ADC is still one of the most aggressive and rapidly fatal tumor types with overall survival less than 5 years. Lung ADC is often diagnosed at advanced stages involving disseminated metastatic tumors. This is particularly important for the successful development of new approaches in cancer therapy. The high resistance of lung ADC to conventional radiotherapies and chemotherapies represents a major challenge for treatment effectiveness. Here we discuss recent advances in understanding the molecular pathways driving tumor progression and related targeted therapies in lung ADCs. In addition, the cell death mechanisms induced by different treatment strategies and their contribution to therapy resistance are analyzed. The focus is on approaches to overcoming drug resistance in order to improve future treatment decisions.

Citing Articles

Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis, metastasis, and drug resistance.

Xiao Y, Hassani M, Moghaddam M, Fazilat A, Ojarudi M, Valilo M Med Oncol. 2025; 42(4):108.

PMID: 40087196 DOI: 10.1007/s12032-025-02675-8.

TIMM23 overexpression drives NSCLC cell growth and survival by enhancing mitochondrial function.

Zha J, Li J, Yin H, Shen M, Xia Y Cell Death Dis. 2025; 16(1):174.

PMID: 40082395 PMC: 11906786. DOI: 10.1038/s41419-025-07505-3.

RFX2 downregulates RASSF1 expression and YAP phosphorylation through Hippo signaling to promote immune escape in lung adenocarcinoma.

Kong Z, Zhou P, Xu J, Zhang Y, Wang Y Cell Div. 2025; 20(1):7.

PMID: 40069841 PMC: 11895337. DOI: 10.1186/s13008-025-00147-z.

Aberrant DNA methylation as a key modulator of cell death pathways: insights into cancer progression and other diseases.

Zahoor A, Khazer R, Mehraj I, Gani U, Fayaz F, Khanday F Funct Integr Genomics. 2025; 25(1):50.

PMID: 40024973 DOI: 10.1007/s10142-025-01552-x.

Integration of single-cell and bulk RNA sequencing to identify a distinct tumor stem cells and construct a novel prognostic signature for evaluating prognosis and immunotherapy in LUAD.

Zhao F, Chen M, Wu T, Ji M, Li F J Transl Med. 2025; 23(1):222.

PMID: 39987127 PMC: 11847374. DOI: 10.1186/s12967-025-06243-6.

References

Zappa C, Mousa S . Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016; 5(3):288-300. PMC: 4931124. DOI: 10.21037/tlcr.2016.06.07. View

Camidge D, Bang Y, Kwak E, Iafrate A, Varella-Garcia M, Fox S . Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13(10):1011-9. PMC: 3936578. DOI: 10.1016/S1470-2045(12)70344-3. View

Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y . Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014; 15(11):1236-44. DOI: 10.1016/S1470-2045(14)70381-X. View

Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K . The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther. 2006; 5(10):2522-30. DOI: 10.1158/1535-7163.MCT-06-0071. View

Hanna N, Kaiser R, Sullivan R, Aren O, Ahn M, Tiangco B . Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Lung Cancer. 2016; 102:65-73. DOI: 10.1016/j.lungcan.2016.10.011. View

Stella G, Luisetti M, Pozzi E, Comoglio P . Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. Lancet Respir Med. 2014; 1(3):251-61. DOI: 10.1016/S2213-2600(13)70009-2. View

Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19):7099-109. DOI: 10.1158/0008-5472.CAN-04-1443. View

Curran M, Montalvo W, Yagita H, Allison J . PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107(9):4275-80. PMC: 2840093. DOI: 10.1073/pnas.0915174107. View

Fujio Y, Walsh K . Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem. 1999; 274(23):16349-54. PMC: 3624707. DOI: 10.1074/jbc.274.23.16349. View

10.

Forde P, Kelly R, Brahmer J . New strategies in lung cancer: translating immunotherapy into clinical practice. Clin Cancer Res. 2014; 20(5):1067-73. DOI: 10.1158/1078-0432.CCR-13-0731. View

11.

Lin K, Cheng J, Yang T, Li Y, Zhu B . EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB. Biochem Biophys Res Commun. 2015; 463(1-2):95-101. DOI: 10.1016/j.bbrc.2015.05.030. View

12.

Alamgeer M, Ganju V, Watkins D . Novel therapeutic targets in non-small cell lung cancer. Curr Opin Pharmacol. 2013; 13(3):394-401. DOI: 10.1016/j.coph.2013.03.010. View

13.

Herbst R, Prager D, Hermann R, Fehrenbacher L, Johnson B, Sandler A . TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23(25):5892-9. DOI: 10.1200/JCO.2005.02.840. View

14.

Fung C, Chen X, Grandis J, Duvvuri U . EGFR tyrosine kinase inhibition induces autophagy in cancer cells. Cancer Biol Ther. 2012; 13(14):1417-24. PMC: 3542232. DOI: 10.4161/cbt.22002. View

15.

Chen Y, Mu C, Huang J . Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori. 2013; 98(6):751-5. DOI: 10.1177/030089161209800612. View

16.

Sequist L, Yang J, Yamamoto N, OByrne K, Hirsh V, Mok T . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3327-34. DOI: 10.1200/JCO.2012.44.2806. View

17.

Pikor L, Ramnarine V, Lam S, Lam W . Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013; 82(2):179-89. DOI: 10.1016/j.lungcan.2013.07.025. View

18.

Li T, Ling Y, Goldman I, Perez-Soler R . Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res. 2007; 13(11):3413-22. DOI: 10.1158/1078-0432.CCR-06-2923. View

19.

Ott P, Hodi F, Kaufman H, Wigginton J, Wolchok J . Combination immunotherapy: a road map. J Immunother Cancer. 2017; 5:16. PMC: 5319100. DOI: 10.1186/s40425-017-0218-5. View

20.

Jackman D, Pao W, Riely G, Engelman J, Kris M, Janne P . Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2009; 28(2):357-60. PMC: 3870288. DOI: 10.1200/JCO.2009.24.7049. View